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ABSTRACT 
Background 
Meta-analysis of small trials suggests that pharmacist-led collaborative review and revision 
of medical treatment may improve outcomes in heart failure. 
 
Methods and results 
We studied patients with left ventricular systolic dysfunction in a cluster-randomised 
controlled, event driven, trial in primary care. We allocated 87 practices (1090 patients) to 
pharmacist intervention and 87 practices (1074 patients) to usual care. The intervention was 
delivered by non-specialist pharmacists working with family doctors to optimise medical 
treatment. The primary outcome was a composite of death or hospital admission for 
worsening heart failure. This trial is registered, number ISRCTN70118765. 
The median follow-up was 4.7 years. At baseline 86% of patients in both groups were treated 
with an angiotensin-converting-enzyme inhibitor or angiotensin-receptor blocker. In patients 
not receiving one or other of these medications, or receiving less than the recommended dose, 
treatment was started, or the dose increased, in 33.1% of patients in the intervention group 
and in 18.5% of the usual care group (odds ratio [OR] 2.26, 95% CI 1.64-3.10; p<0.001). At 
baseline, 62% of each group were treated with a β-blocker and the proportions starting or 
having an increase in dose were 17.9% in the intervention group and 11.1% in the usual care 
group (OR 1.76, 95% CI 1.31-2.35; p<0.001). The primary outcome occurred in 35.8% of 
patients in the intervention group and 35.4% in the usual care group (hazard ratio 0.97, 95% 
CI 0.83-1.14; p = 0.72). There was no difference in any secondary outcome.  
 
Conclusion 
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A low-intensity, pharmacist-led, collaborative intervention in primary care resulted in modest 
improvements in prescribing of disease-modifying medications but did not improve clinical 
outcomes in a population that was relatively well treated at baseline.  
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INTRODUCTION 
Although angiotensin-converting-enzyme (ACE) inhibitors, angiotensin-receptor blockers 
(ARB) and β-blockers reduce morbidity and mortality in patients with heart failure due to left 
ventricular systolic dysfunction, there is evidence that these treatments are underused, 
particularly in primary care.1-5 Some patients who should receive these medications do not 
and many receive less than evidence-based doses.2-5 Pharmacists may play a role in 
improving treatment through “collaborative medication review”, a process in which the 
pharmacist evaluates a patient’s medications and suggests changes which are enacted with the 
agreement of the patient and the family doctor.6-9 A meta-analysis of small, short-term, trials 
and observational data suggest that this intervention reduces the risk of hospital admission 
and possibly mortality in patients with heart failure studied in a secondary care setting.6-10 We 
conducted a larger-scale, longer-term, prospective randomised controlled trial to test the 
hypothesis that a low-cost, low-intensity, pharmacist intervention to optimise medical 
treatments, particularly ACE inhibitors, ARBs, and β-blockers, in patients identified in 
primary care with left ventricular systolic dysfunction would reduce the composite outcome 
of hospital admission for worsening heart failure or death, as well as other clinically 
important outcomes. 
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METHODS 
 
Study design and patients 
The study was conducted within the National Health Service (NHS) which provides free 
health care to the population of the United Kingdom. The design of our trial has been 
published and was consistent with Consolidated Standards of Reporting Trials.11-13 
Consenting patients were eligible if aged 18 years or older and had left ventricular systolic 
dysfunction confirmed by cardiac imaging conducted at a local hospital (transthoracic 
echocardiography in 90% of cases). Patients did not have to have symptoms or signs of heart 
failure. Family doctors receive a semi-quantitative report of left ventricular systolic function 
(normal; mild, moderately or severely reduced) instead of ejection fraction.  A key exclusion 
criterion was registration with the heart failure-nurse service which is provided to patients in 
our Health Board area recently admitted to hospital with heart failure. This criterion excluded 
higher risk patients with more severe symptoms. Other exclusion criteria included concurrent 
disease other than heart failure likely to reduce life-expectancy; severe cognitive impairment 
or psychiatric illness; dialysis, or a resident in a long-term care facility. The study was 
approved by the local ethics committee. All practices and patients gave written informed 
consent. The study is registered, number ISRCTN70118765. 
 
 
Randomisation 
We used a cluster-randomisation design as this provides protection against contamination 
across trial groups when trial patients are managed within the same setting as was the case in 
this study. Patients in practices in the UK are managed by all general practitioners within the 
practice; as the control intervention was mediated by general practitioners, this precluded 
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individual patient level randomisation. Family practices were randomly allocated using a 
third-party automated telephone interactive voice response system in a 1:1 ratio to receive 
intervention or usual care. Stratification was by socioeconomic deprivation (affluent, 
intermediate or deprived) at practice level, and practice-type (single-handed or group-
practice).11
 
Study procedures 
The intervention was delivered by 27 primary care-based pharmacists employed by the NHS 
to work with family doctors and directly with patients to promote rational, cost-effective 
prescribing.14 All participating pharmacists had between three and 16 years of post-
qualification experience. All had experience delivering primary care based medication review 
clinics for patients receiving multiple drug treatment. Seven pharmacists held postgraduate 
clinical pharmacy qualifications. Four pharmacists had hospital (ward-based) clinical 
pharmacy experience. Prior to commencing the intervention, all pharmacists attended one, in-
house training day (contact time 7.5 hours) covering the aetiology, symptoms and evidence-
based management of heart failure. The day was co-ordinated by three pharmacists who had a 
special interest in heart failure therapeutics, and a general practitioner with a special interest 
in heart failure. The day comprised of a mixture of didactic teaching and interactive role-play 
sessions. An additional mandatory three-hour session covered the methods of the trial. All 
pharmacists received an information pack with directed, heart failure-specific reading to 
supplement their training. 
 
As part of routine continuing professional development, each pharmacist participated in a 3.5 
hour peer-led session every month which involved group-discussion of cases encountered in 
their medication-review clinics. As the study pharmacists were embedded within primary 
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care practices, informal discussion on therapeutics occurred regularly between pharmacists, 
general practitioners and nurses within the practice. There was also regular telephone-contact 
between study pharmacists and the principal investigator or another pharmacist with a special 
interest in heart failure. 
Patients from practices assigned to the intervention were offered a 30 minute appointment 
with a pharmacist. The main aim of this review was optimisation of medical treatment for left 
ventricular systolic dysfunction according to guidelines (see Supplementary data). If there 
was agreement between the pharmacist and patient during the consultation and subsequently 
with the family doctor, medications were initiated, discontinued or modified by the 
pharmacist during three to four subsequent weekly or fortnightly consultations. Family 
doctors provided usual care thereafter. No instructions were given to family doctors in the 
usual care practices. The study pharmacists did not collect information on symptoms or 
examine the patients as this was not part of their professional training. The cause of heart 
failure was established by scrutinising primary and secondary care (e.g. hospital letters and 
discharge summaries) clinical records.  
 
Study outcomes 
The primary outcome was the composite of death from any cause or hospital admission for 
worsening heart failure, analysed as time to first event. Secondary endpoints included the 
composites of death from any cause or hospital admission for pre-specified cardiovascular 
causes (see Supplementary data), death from any cause or hospital admission for any cause; 
total number of admissions (and patients admitted) for heart failure, cardiovascular causes 
and any cause; and days alive out of hospital. Outcome data were obtained from the 
Information Services Division (ISD) of the NHS in Scotland, which records all discharges 
from Scottish NHS hospitals (i.e. virtually all hospital admissions in Scotland) and the 
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General Register Office which records all deaths. Hospital discharge data are reported to ISD 
with discharge diagnoses coded according to the International Classification of Diseases 
(ICD) system, 10th revision.15,16  This approach to patient follow-up has been compared 
favourably to traditional clinical trial methods.17,18  Although the end-of-study date was 
January 31, 2011, data-extraction did not occur until July 25, 2011 in order to ensure that all 
deaths and hospital admissions were entered into the national database.  
We also compared the prescribing of medications between the intervention and usual care 
groups and evaluated health-care utilisation, other than admissions, at one and two years of 
follow-up e.g. the number of primary care contacts and hospital emergency room visits.  
 
Statistical analysis 
The trial data were managed and analysed by the Robertson Centre for Biostatistics, 
University of Glasgow. The primary analysis compared the main outcomes between the 
intervention and control groups using a Cox proportional hazards frailty model, which 
accounted for the cluster-randomisation design.11-13 These analyses were adjusted for the 
stratification variables and the following variables of prognostic importance: age, creatinine, 
grade of left ventricular systolic dysfunction, atrial fibrillation, respiratory disease, total 
number of medical treatments, and diuretic use.  
We initially assumed the rate of the primary outcome would be 10% per year in the control 
group and pharmacist intervention would lead to a relative risk reduction of 26%, based upon 
the known benefits of initiating disease-modifying treatment and of higher doses of those 
therapies.1, 19, 20 Due to the cluster-randomisation design, the sample size needed to be 
increased by a factor of 1.55.11-13 Consequently 87 practices (1044 patients) were required in 
each group. Blinded review of patient data in September 2010 suggested that 750 patients 
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would experience a primary outcome event at follow-up, providing 80% power to detect a 
19% relative risk reduction with the intervention. 
 
Logistic regression models were used to examine secondary outcomes including whether 
patients started or stopped a medical treatment or had a change in dose.  
 
Safety was evaluated by examining hospital admissions for: symptomatic hypotension, 
collapse or syncope; renal dysfunction, failure or impairment; hyperkalaemia; asthma or 
chronic obstructive pulmonary disease; and bradycardia, atrioventricular block or pacemaker 
implantation. Fisher’s exact t-test was used to compare the intervention group with the usual 
care group.  
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RESULTS 
Study patients 
All general practices in our locality were approached and 174 of 220 (79%) practices 
(covering 790,421 of 998,402 i.e.79% of patients registered with a general practitioner in our 
Health Board area) took part in the trial. From October 25 2004, through September 6, 2007, 
87 primary care practices (1090 patients) were randomly assigned to pharmacist intervention 
and 87 practices (1074 patients) to usual care (Figure 1). One patient had incomplete follow-
up due to emigration. The median duration of follow-up was 4.7 years (range 6 days to 6.2 
years; 9362 patient-years). 
The two groups were balanced with respect to baseline characteristics (Table 1). Fifty five 
percent of patients were aged 70 years or older. There was a high prevalence of ischaemic 
heart disease (80%) and respiratory disease (30%). A semi-quantitative assessment of left 
ventricular function was recorded in 2023 (93%) patients, with most having either mild 
(41%) or moderate (42%) reduction in systolic function. In a small reasonably representative 
subset of patient records (n=256; 12%) there was documentation of a LVEF value along with 
a semi-quantitative assessment of systolic function. In these patients the mean ejection 
fraction was 36.8% (standard deviation 6.5%) in those with mildly reduced systolic function, 
30.5% (7.5%) in those with moderately reduced function and 19.7% (7.7%) in patients with 
severely reduced function.  
Although general practitioners do not routinely record New York Heart Association (NYHA) 
class in our area (and NYHA class was not recorded by the study pharmacists) this measure 
was documented in the records of 337 patients; 85 (25%) were NYHA class I; 219 (65%) 
were NYHA class II; 30 (9%) were NYHA class III and 3 (1%) were in NYHA class IV. 
Very few (1.7%) patients had been admitted to hospital for heart failure in the year prior to 
randomisation. 
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 Medical treatment  
In each treatment group, approximately 86% of patients were receiving an ACE inhibitor, 
ARB or both (Table 1) and of these patients, 55% received 100% or more of the 
recommended dose. The proportion of patients receiving a β-blocker was 62% in each 
treatment group. Of these, 21% were treated with 100% or more of the recommended dose 
(Table 1).  
Patients not prescribed an ACE inhibitor, ARB or β-blocker, or not prescribed the 
recommended doses of these medications at baseline, were potentially eligible for treatment 
optimisation. Table 2 shows the effect of pharmacist intervention (patients who died during 
the first and second years of follow-up were excluded from this analysis - dead patients could 
not receive the intervention). Pharmacist intervention during the first year of the trial led to a 
greater frequency of initiation of an ACE inhibitor or ARB and a β-blocker, compared with 
usual care (Table 2). The same was true for increases in the dose of these treatments. By the 
end of year one, an ACE inhibitor or ARB was started or the dose was increased in 168/507 
(33.1%) of patients in the intervention group and 95/514 (18.5%) of patients in the usual care 
group (odds ratio [OR] 2.26, 95% CI 1.64-3.10, p<0.001). The proportions starting or having 
an increase in dose of β-blocker were 153/854 (17.9%) of patients in the intervention group 
and 95/855 (11.1%) of patients in the usual care group (OR 1.76, 95% CI 1.31-2.35, 
p<0.001). The resultant proportion of patients receiving an ACE inhibitor, ACE inhibitor or 
ARB and beta-blocker at the end of year 1 and year two is shown in table 3, as well as the 
proportions of those patients receiving at least 50% and at least 100% of the recommended 
dose.  At the end of year one of follow-up the proportion of patients in the pharmacist 
intervention group receiving at least 100% of the recommended dose of ACE inhibitor was 
66.4% compared with 61.5% in the usual care group; these proportions were 60.9% versus 
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55.3% for an ACE inhibitor or ARB and 26.2% versus 22.4% for a beta-blocker. The 
proportions at year 2 were 67.5% versus 59.5%, 61.4% versus 53.9% and 27.1 versus 22.5%, 
respectively. These differences were sustained during the second year with no evidence of 
“catch-up” prescribing in the usual care group (see Supplementary data). There was no 
difference between treatment-groups regarding dose-reduction, or discontinuation of these 
drugs. The proportion of patients collecting 80% or more of prescriptions (from their general 
practice) was 99% in the pharmacist intervention group versus 99% in the usual care group 
for ACE inhibitors, 98% versus 98% for ARBs and 98% versus 99% for beta-blockers (no 
difference between treatment groups for any drug). 
At the end of year 1, 5.0% of the pharmacist intervention group and 4.6% in the usual care 
group were prescribed an aldosterone antagonist. At the end of year 2 the proportions were 
5.1% and 5.2%.  
At baseline diltiazem or verapamil was used in 132 (6%) of patients, a non-steroidal anti-
inflammatory drug in 144 (7%), an anti-depressant in 223 (10%) [a tricyclic in 73 (3%)] and 
a glitazone in 17 (1%). These drugs were discontinued more often in the pharmacist 
intervention group in the first year but the difference in rates of discontinuation between the 
two treatment groups were not statistically significant (see Supplementary data).  
 
Study outcomes 
Death from any cause or hospital admission for heart failure (the primary outcome) occurred 
in 390 patients (35.8%) in the intervention group and 380 patients (35.4%) in the usual care 
group (Figure 2 and Table 4). The adjusted hazard ratio [HR] for the primary outcome in the 
intervention group, as compared to the usual care group, was 0.97, 95% CI 0.83-1.14, 
p=0.72). The effect of the intervention on this outcome was consistent in an unadjusted 
analysis (Table 4) and across all pre-specified subgroups (Figure 3).  
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Death from any cause or hospital admission for a cardiovascular cause occurred in 487 
patients (44.7%) in the intervention group as compared with 475 patients (44.2%) in the usual 
care group (HR 0.97, 95% CI 0.84-1.12, p = 0.70). A total of 337 patients (30.9%) in the 
intervention group and 331 patients (30.8%) in the usual care group died (HR 0.96, 95% CI 
0.80-1.16, p=0.68). The number of deaths attributed to a non-cardiovascular cause was 155 in 
the intervention group and 169 in the usual care group. 
 
The number of patients admitted to hospital for any reason, for a cardiovascular cause and for 
heart failure was similar in the two treatment groups (Table 4). The total numbers of hospital 
admissions (including second and subsequent hospital admissions) for any reason were 2205 
versus 2191 (P=0.84), for cardiovascular causes 474 versus 517 (P=0.19) and for heart failure 
149 versus 194 (P=0.08), in the intervention group and usual care group, respectively. 
Findings for the other pre-specified secondary outcomes and safety outcomes are reported in 
the Supplementary data. 
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DISCUSSION 
Although a meta-analysis of small, short-term, studies suggested that pharmacist intervention 
improves clinical outcomes in patients with heart failure7, we did not confirm this in a much 
larger and longer trial conducted in primary care, despite the intervention leading to 
improvements in the use of disease-modifying medications which persisted for at least two 
years. 
There are a number of possible explanations for this finding.  The frequency of use of ACE 
inhibitors and ARBs at baseline was greater than reported in previous studies in primary care, 
and even in our pilot study, with 86% of patients prescribed at least one of these 
medications.2-5,21  The explanation for this unexpected finding is uncertain although in 2004, 
the year our trial started, the United Kingdom government introduced a new contract for 
family doctors linking pay to performance.22,23Prescribing of ACE inhibitors (but not β-
blockers) in patients with left ventricular systolic dysfunction was one of the incentivised 
activities. As a consequence of the high baseline use of ACE inhibitors and ARBs, there was 
little scope to initiate these agents.  There was also limited opportunity to increase the dose of 
these drugs as a high proportion (55%) of subjects was already receiving the recommended 
dose at baseline. Furthermore, dose was increased in only about a third of eligible patients in 
the intervention group (compared with 19% of those in the usual care group), presumably 
because of tolerability and safety considerations, perhaps indicating that the rate of use and 
dosing of these drugs may have already approached a ceiling level.  Certainly, the rate of use 
of ACE inhibitors and ARBs and the doses that they were used at in our trial equal or exceed 
those in recent heart failure trials (despite our patients being more elderly than in these other 
trials)24,25 and a national audit in the United Kingdom26. 
 
  15
Although there was more scope to improve β-blocker prescribing, initiation of this type of 
medication and increase in dose of β-blocker was infrequent in both treatment groups.  This 
lack of success may indicate that the brief period of tuition used to prepare the non-specialist 
pharmacists in our trial was insufficient. Unfamiliarity with the use of β-blockers, and 
persisting concerns about their tolerability and safety, in left ventricular systolic dysfunction 
amongst family doctors at the time our trial started, as well as the high prevalence of 
respiratory disease in our population may also have limited β-blocker use. Additionally, 
patients may also have been unwilling to take an additional medication given the high rate of 
multi-drug regimens in the population studied (47% were receiving more than 8 
medications). Nevertheless, although the rate of use of beta-blockers was disappointing, the 
proportion of patients taking 100% or more of the recommended dose of beta-blocker by the 
end of the first year in the pharmacist intervention group (26%) compared favourably with 
the Systolic Heart failure treatment with If inhibitor ivabradine Trial (SHIFT) where this 
proportion was 26% at baseline.24
 
A second explanation for the lack of effect of our intervention was the relatively low 
frequency of hospital admission for heart failure which meant that the majority of events 
contributing to the primary composite outcome were fatal.  In addition, only half of the 
deaths that occurred were attributed to cardiovascular causes.  We excluded high-risk patients 
under the care of specialist heart failure nurses. Furthermore, falling hospital admission rates 
for heart failure have been reported in several countries15,27-31 and, recently, cardiovascular 
deaths, as a proportion of overall deaths, have also been reported to be declining in patients 
with heart failure.32  Consequently, there were fewer non-fatal and fatal events which might 
have been reduced through greater use of ACE inhibitors, ARBs and β-blockers. We believe 
that these two factors – only a modest improvement in use of disease-modifying treatment 
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coupled with a low rate of modifiable events – are the most likely explanation for a lack of 
improvement in clinical outcomes in our trial. 
The low rate of use of aldosterone antagonists in our trial was due to the exclusion of more 
severely ill patients who were under the care of the specialist heart failure nurse service and 
hospital clinics. At the time of our trial aldosterone antagonists were only indicated in such 
patients.1  Clearly, if such a trial were repeated today, use of aldosterone antagonists would be 
encouraged by pharmacists. 
Potentially harmful medications e.g. rate-limiting calcium channel blockers, non-steroidal 
anti-inflammatory drugs, tricyclic antidepressants, oral corticosteroids and glitazones were 
prescribed in a very small proportion of patients at baseline and pharmacist intervention did 
not lead to any greater discontinuation of these medicines, as compared with usual care 
during follow-up. 
As explained in the Methods section, we had to use a cluster randomisation design. We 
ensured good internal validity by accounting for the clustered nature of the data in our sample 
size calculations and ensuring blinding to allocation status of those recruiting individuals into 
the trial and good external validity by providing information on numbers approached, 
recruited and lost to follow-up. We therefore followed best practices in relation to this type of 
trial.  Furthermore, although a major limitation of this design is lack of similarity of the study 
groups, our treatment groups were well matched.12,13
There were several limitations to our trial. The study pharmacists were not trained to elicit 
signs and symptoms of heart failure. We did not collect reasons why patients might have been 
ineligible for a specific treatment or unable to tolerate it (collecting this information on the 
control group might have caused contamination). Ejection fraction was not reported to 
general practitioners and natriuretic peptides measurements were not available in primary 
care at the time our patients were recruited. Although our trial did not achieve its goal of 
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improving clinical outcomes it did demonstrate that modest and sustained improvements in 
the prescribing of disease-modifying medications can be achieved by a brief, focused, 
collaborative intervention delivered by non-specialist pharmacists given only a short period 
of training.  However, the short period of training and brevity of intervention may also have 
been limitations of our study. This was particularly true in relation to beta-blockers where our 
intervention had a disappointingly small effect on the use of these drugs. Lessons for future 
trials may be that more intense training, more patient visits and selective involvement of 
hospital specialists might be required to fully optimise treatment. It is also possible that 
modification of other treatments that we didn’t target, such as diuretics may have improved 
outcome and this could also be examined in future studies. While this type of intervention 
may not benefit all patients, it might improve clinical outcomes if aimed at those in most 
need in terms of deficient background treatment or at those at higher risk of modifiable 
events. This is a question that may be considered in future comparative-effectiveness trials. 
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FIGURE LEGENDS 
 
Figure 1 Study Recruitment 
 
Figure 2 Main Study Outcomes 
 
Figure 3 Sub-group analysis for the primary outcome. 
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Table 1. Baseline characteristics of patients, according to study group.* 
Characteristic Pharmacist  
intervention 
(n=1092)** 
Usual care 
 
(n=1077)** 
Age (years) 70.6 (10.3) 70.6 (10.1) 
Age ≥ 70 years  597 (55%) 597 (55%) 
Sex (female) 320 (29%) 329 (31%) 
Blood pressure a
SBP (mm Hg) 
DBP (mm Hg) 
 
127 (17.4) 
72 (10.1) 
 
128 (17.4) 
72 (10.2) 
Left ventricular systolic function (%)b
Mild reduction 
Moderate reduction 
Severe reduction 
 
433 (43%) 
416 (41%) 
170 (17%) 
 
390 (39%) 
439 (44%) 
175 (17%) 
BMI  (kg/m2) c 28.0 (5.4) 28.0 (5.4) 
Principal cause of heart failure (%) 
Ischaemic heart disease 
Non ischaemic heart disease 
Unknown 
 
874 (80%) 
197 (18%) 
21 (2%) 
 
817 (76%) 
230 (21%) 
30 (3%) 
Duration of LVSD  (years)d 3.31 (1.54, 5.85) 3.53 (1.76, 5.87) 
Medical history  
Admission for heart failure in past year 
Hypertension 
Myocardial infarction 
 
19 (2%) 
548 (50%) 
722 (66%) 
 
18 (2 %) 
495 (46%) 
665 (62%) 
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PCI 
CABG 
Atrial fibrillation or flutter 
Diabetes mellitus 
Stroke 
Respiratory disease 
Asthma 
Smoker 
161 (15%) 
266 (24%) 
292 (27%) 
234 (22%) 
148 (14%) 
326 (30%) 
72 (7%) 
262 (24%) 
144 (13%) 
268 (25%) 
304 (28%) 
212 (20%) 
162 (15%) 
318 (30%) 
82 (8%) 
260 (25%) 
Serum creatinine (µmol/L)e 109 (33) 107 (30) 
eGFR (mL/min per 1.73m2) f 61.3 (17.5) 62.6 (23.2) 
Device treatment (%)g
Implantable cardioverter-defibrillator 
Conventional pacemaker 
 
19 (2%) 
22 (2%) 
 
12 (1%) 
29 (3%) 
Cardiac medicines at randomisation (%) 
ACE inhibitor  
> 50% recommended dose§
> 100% recommended dose§
ARB 
> 50% recommended dose§
> 100% recommended dose§
ACE inhibitor or ARB or both 
Β-blocker 
> 50% recommended dose§
> 100% recommended dose§
Aldosterone antagonist 
 
814 (75%) 
695 (86%) 
483 (60%) 
149 (14%) 
102 (69%) 
34 (23%) 
944 (87%) 
674 (62%) 
339 (51%) 
146 (22%) 
54 (5%) 
 
768 (71%) 
656 (86%) 
472 (62%) 
181 (17%) 
107 (59%) 
35 (19%) 
919 (85%) 
664 (62%) 
339 (52%) 
128 (20%) 
56 (5%) 
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Digitalis glycoside 
Diuretic 
Aspirin 
Antithrombotic (antiplatelet or oral anticoagulant) 
Amiodarone 
Lipid lowering agent 
149 (14%) 
667 (61%) 
751 (69%) 
990 (91%) 
20 (2%) 
863 (79%) 
124 (11%) 
654 (61%) 
691 (64%) 
969 (90%) 
32 (3%) 
841 (78%) 
Number of medicines† 8.9 (4.0) 8.4 (3.5) 
Data are numbers of patients (%) or mean (SD).  Percentages may not total 100 because of rounding.  
** 5 patients (2 intervention, 3 usual care) died before randomisation.  SBP=systolic blood pressure. 
DBP = diastolic blood pressure. BMI = body mass index. PCI = percutaneous coronary intervention.  
CABG = coronary-artery bypass grafting.  eGFR=estimated glomerular filtration rate. ACE = 
angiotensin-converting enzyme. ARB = angiotensin receptor blocker. § Percentage of those prescribed 
an ACE inhibitor, ARB or β-blocker and with dose recorded. 
† Medicines on repeat prescription. 
Data missing for a83; b146; c154; d36; e296; f302; g3 patients. 
Table 2. Changes in key disease-modifying medicines between baseline and the end of the first year of follow-up.†
 
Medical treatment 
Pharmacist 
Intervention 
 
Usual Care 
Odds Ratio 
(95% CI) 
 
P value 
 n (%)   
ACE inhibitor or ARB†
Started* 
Increased dose** 
Increased dose to ≥ 100% of target** 
Started or increased dose 
 
39/131 (30%) 
129/376 (34%) 
86/376 (23%) 
168/507 (33%) 
 
27/149 (18%) 
68/365 (19%) 
40/365 (11%) 
95/514 (19%) 
 
2.03 (1.14-3.60) 
2.32 (1.57-3.44) 
2.46 (1.51-3.99) 
2.26 (1.64-3.10) 
 
0.02 
<0.001 
<0.001 
<0.001 
Β-blocker†
Started* 
Increased dose** 
Increased dose to ≥ 100% of target** 
Started or increased dose 
 
50/388 (13%) 
103/466 (22%) 
38/466 (8%) 
153/854 (18%) 
 
35/388 (9%) 
60/467 (13%) 
22/467 (5%) 
95/855 (11%) 
 
1.56 (0.98-2.47) 
1.90 (1.29-2.79) 
1.75 (0.99-3.09) 
1.76 (1.31-2.35) 
 
0.06 
0.001 
0.05 
<0.001 
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* Of patients not taking this medicine at baseline ** Of patients taking this medicine at baseline but at < 100% of the target dose and had dose 
recorded (number with missing dose: ACE inhibitor ARB n=1; β-blocker n=12) 
† Patients who died (n = 106) or were lost to follow-up (n = 2) during the first year of follow-up were not included in this analysis 
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Table 4. Primary and Main Secondary Outcomes  
Outcome Pharmacist Intervention
 
(n = 1090) 
Usual care 
 
(n = 1074) 
 Patients
with Event
 Event Rate 
n/100 
Patients 
with Event 
Event Rate 
n/100 
Adjusted Hazard 
Ratio 
(95% CI) 
 
Adjusted
P Value 
Unadjusted 
Hazard Ratio 
(95% CI) 
 
Unadjusted 
P Value 
         patient-yr patient-yr
Primary outcome 
Death from any cause or 
admission for heart 
failure* 
 
 
390 (36%) 
 
8.53 
 
380 (35%) 
 
8.57 
 
0.97 (0.83-1.14) 
 
0.72 
 
0.99 (0.87- 1.13) 
 
0.91 
Main secondary outcomes 
Death from any cause or 
admission for 
cardiovascular cause 
 
487 (45%) 
 
 
 
11.54 
 
 
 
475 (44%) 
 
 
 
11.67 
 
 
 
0.97 (0.84-1.12) 
 
 
 
0.70 
 
 
 
0.98 (0.87-1.11) 
 
 
 
0.81 
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 Death from any cause or 
admission for any reason 
 
Admissions 
        Heart failure 
        Cardiovascular causes 
        Any reason 
Death 
 
758 (70%) 
 
 
 
107 (10%) 
292 (27%) 
711 (65%) 
337 (31%) 
 
24.93 
 
 
 
2.34 
6.92 
23.38 
7.10 
 
751 (70%) 
 
 
 
114 (11%) 
280 (26%) 
695 (65%) 
331 (31%) 
 
25.46 
 
 
 
2.57 
6.88 
23.56 
7.18 
 
0.96 (0.86-1.07) 
 
 
 
0.88 (0.67-1.16) 
0.98 (0.81-1.19) 
0.97 (0.87-1.09) 
0.96 (0.80-1.16) 
 
0.41 
 
 
 
0.36 
0.83 
0.61 
0.68 
 
0.97 (0.88-1.07) 
 
 
 
0.90 (0.71-1.14) 
0.99 (0.84-1.18) 
0.98 (0.89-1.08) 
0.99 (0.85-1.16) 
 
0.55 
 
 
 
0.38 
0.94 
0.73 
0.92 
* The number of events contributing to the primary composite in the intervention group was 283 deaths and 107 admissions for heart failure and 
in the usual care group 266 deaths and 114 admissions for heart failure.
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Figure 1 
 
 
§ 5 patients (from 5 practices; 2 intervention and 3 usual care) died in the period between baseline data 
collection and practice randomisation.  
* Information on treatment unavailable for 2 patients between baseline year 1 and one additional patient 
between the end of year 1 and end of year 2 
LVSD = left ventricular systolic dysfunction 
 
 
220 practices (population: 998,402) invited              
Aug 2004 – June 2007  
Excluded: 46 practices (population 207,981). 
Reasons: no reply (6), declined (37), agreed 
after recruitment stopped (3) 174 practices (population: 790,421) consented          
Aug 2004 – Jun 2007      
6,716 patients with possible LVSD identified through 
searches in 174 practices, assessed for eligibility     
Aug 2004 – Sep 2007 
4,296 did not reply or declined 
155 patients not eligible for randomisation: 
referred to heart failure nurse-specialist (79), 
died (24), withdrew consent (23), moved away 
(8), terminal-illness (9), entered care-home (2), 
dialysis (10) 
87 practices (1074 
patients) assigned to 
usual care
87 practices (1090 
patients) assigned to 
pharmacist intervention 
2,324 patients from 174 practices consented            
Oct 2004 – Sep 2007      
6620 patients (174 practices) eligible and invited to 
participate           
96 excluded (LVSD not confirmed) 
2,169 patients (174 practices) with baseline 
data collected     Oct 2004 – Sep 2007 
2164 patients (174 practices) followed up 6 days – 6.2 years 
post-randomisation* 
5 patients died before randomisation§
174 practices (2,164 patients) randomised   
Oct 2004 – Sep 2007 
Figure 2
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Figure 3 
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